Stock Chart

SKYE

$1.54 -4.94%
Score: 52.5 HOLD
Pro
Screener
Vol: 0.41x (vs SPY: 0.5x | vs QQQ: 0.5x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 23, 2026
Falling Wedge Bullish scenario quality 67/100
Measured-move target $1.64 (+6.5%) · apex ~8 bars ahead
Historically breaks up 63% of the time; target hit in 75% of up-breaks (n=385)
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and target are drawn on the chart below.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About SKYE - Skye Bioscience, Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a …

Key Statistics

Market Cap $7M

More SKYE Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This SKYE stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track SKYE's price movements with trendlines, gamma walls, and key support/resistance levels.